Sridhar Ramaswamy
Overview
Explore the profile of Sridhar Ramaswamy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
22293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Friedman A, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper Z, Piris A, et al.
PLoS One
. 2024 Jul;
19(7):e0306658.
PMID: 38950005
[This corrects the article DOI: 10.1371/journal.pone.0140310.].
2.
Murugesan A, Kumaragurubaran K, Gunasekaran K, Murugasamy S, Arunachalam S, Annamalai R, et al.
Vet Res Commun
. 2023 Nov;
48(2):955-968.
PMID: 38032521
Hemoplasma are small pleomorphic wall-less Gram-positive bacteria that infect erythrocytes of various mammalian hosts. They generally cause asymptomatic or chronic anaemia but occasionally causes overt life-threatening hemolytic anaemia. In the...
3.
Kumar S, Ghosh S, Sharma G, Wang Z, Kehry M, Marino M, et al.
MAbs
. 2021 Jul;
13(1):1954136.
PMID: 34313545
Inhibitors of programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have dramatically changed the treatment landscape for patients with cancer. Clinical activity of anti-PD-(L)1 antibodies has resulted in...
4.
Koh S, Ross K, Isakoff S, Melkonjan N, He L, Matissek K, et al.
Clin Cancer Res
. 2021 Jun;
27(17):4883-4897.
PMID: 34168046
Purpose: While chemotherapy remains the standard treatment for triple-negative breast cancer (TNBC), identifying and managing chemoresistant tumors has proven elusive. We sought to discover hallmarks and therapeutically actionable features of...
5.
Qiao S, Koh S, Vivekanandan V, Salunke D, Patra K, Zaganjor E, et al.
Genes Dev
. 2020 Apr;
34(11-12):751-766.
PMID: 32273287
Human cancers with activating mutations are typically highly aggressive and treatment-refractory, yet mutation itself is insufficient for tumorigenesis, due in part to profound metabolic stress induced by RAS activation. Here...
6.
Karaayvaz-Yildirim M, Silberman R, Langenbucher A, Saladi S, Ross K, Zarcaro E, et al.
Sci Adv
. 2020 Feb;
6(5):eaay2611.
PMID: 32064343
Women harboring heterozygous germline mutations of have a 50 to 80% risk of developing breast cancer, yet the pathogenesis of these cancers is poorly understood. To reveal early steps in...
7.
Etchegaray J, Zhong L, Li C, Henriques T, Ablondi E, Nakadai T, et al.
Mol Cell
. 2019 Aug;
75(4):683-699.e7.
PMID: 31399344
Transcriptional regulation in eukaryotes occurs at promoter-proximal regions wherein transcriptionally engaged RNA polymerase II (Pol II) pauses before proceeding toward productive elongation. The role of chromatin in pausing remains poorly...
8.
Kabraji S, Sole X, Huang Y, Bango C, Sgroi D, Loda M, et al.
NPJ Breast Cancer
. 2019 Mar;
5:10.
PMID: 30911675
Ductal carcinoma in situ (DCIS) of the breast precedes the development of invasive breast cancer and reflects the genomic changes and protein expression profile of invasive disease. AKT1 cancer cells...
9.
Zheng Y, Comaills V, Burr R, Boulay G, Miyamoto D, Wittner B, et al.
Proc Natl Acad Sci U S A
. 2019 Mar;
116(12):5223-5232.
PMID: 30819896
Tumor-stromal communication within the microenvironment contributes to initiation of metastasis and may present a therapeutic opportunity. Using serial single-cell RNA sequencing in an orthotopic mouse prostate cancer model, we find...
10.
Amzallag A, Ramaswamy S, Benes C
BMC Bioinformatics
. 2019 Feb;
20(1):83.
PMID: 30777010
Background: Drug combinations have the potential to improve efficacy while limiting toxicity. To robustly identify synergistic combinations, high-throughput screens using full dose-response surface are desirable but require an impractical number...